<DOC>
	<DOC>NCT01357980</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and safety of a single dose of 750 U of Dysport compared to placebo for the improvement in the daily incontinence episode frequency for each administration mode in subjects suffering from neurogenic detrusor overactivity following spinal cord injury or multiple sclerosis.</brief_summary>
	<brief_title>Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Subject, family member or care giver was willing and able to perform clean intermittent catheterisation (CIC) for the duration of the study Inadequate response or refractory to anticholinergic medication Botulinum Toxin naive for intradetrusor injections and with no previous treatment with Botulinum Toxin of any type, within 3 months prior to study entry for any other condition Have a minimum of 2 incontinences per day calculated as the average daily incontinence episode frequency (IEF) over the 3 days preceding the baseline visit Significant Baseline renal and/or urinary tract pathology Previous treatment with any endovesical pharmacology agent including detrusor Botulinum Toxin injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Detrusor Muscle Overactivity</keyword>
</DOC>